Related Experiment Video
Updated: Jul 16, 2025
08:00
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
6.2K
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
Istemi Serin1, Omur Gokmen Sevindik2, Berrin Balik Aydin2
1University of Health Sciences, Istanbul Training and Research Hospital, Department of Hematology, Istanbul, Turkey.
Summary
Plerixafor use in stem cell mobilization may delay engraftment and increase febrile neutropenia after autologous stem cell transplantation (ASCT). Further research is needed to fully understand plerixafor
Area of Science:
- Hematology
- Transplantation Medicine
- Pharmacology
Background:
- Plerixafor is a CXCR4 antagonist used for stem cell mobilization.
- Granulocyte colony-stimulating factor (G-CSF) is a standard mobilization agent.
- Autologous stem cell transplantation (ASCT) relies on effective stem cell mobilization.
Purpose of the Study:
- To evaluate the impact of plerixafor on stem cell mobilization and engraftment kinetics in ASCT.
- To compare engraftment times and adverse events between patients mobilized with and without plerixafor.
Main Methods:
- Retrospective analysis of 300 ASCT cases at xxx University (2014-2022).
- Comparison of CD34+ cell collection, neutrophil and platelet engraftment times.
- Analysis of febrile neutropenia incidence in plerixafor-mobilized versus non-mobilized patients.
Main Results:
- Plerixafor mobilization yielded fewer CD34+ cells compared to standard mobilization.
- Neutrophil and platelet engraftment were significantly delayed in patients mobilized with plerixafor.
- Higher incidence of febrile neutropenia was observed in plerixafor-mobilized patients, particularly in the chemo-mobilized subgroup.
Conclusions:
- Plerixafor use is associated with delayed engraftment and increased febrile neutropenia post-ASCT.
- The findings suggest a need for careful consideration of plerixafor in ASCT protocols.
- Further large-scale studies are warranted to confirm these effects and assess survival outcomes.
